J. Goldman & Co’s Altimmune ALT Stock Holding History

J. Goldman & Co’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-27,000	Closed	-$275K	–	434
2024 Q1	$275K	Buy	+27,000	New	+$275K	0.01%	355

Other funds holding ALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

J. Goldman & Co's ALT Position: Q4 2022 in Review

J. Goldman & Co sold out of Altimmune (ALT) in Q4 2022, closing a stake of 55,935 shares — an estimated $714K sold.

J. Goldman & Co first reported a position in ALT in Q3 2013 and held it in 7 quarters. The position peaked at $714K in Q3 2022. 128 funds tracked by Wall St. Rank hold ALT as of Q4 2022.

J. Goldman & Co reported no remaining Altimmune position as of Q4 2022 after selling out during the quarter.
J. Goldman & Co sold 55,935 Altimmune shares in Q4 2022, an estimated $714K.
J. Goldman & Co first reported a position in Altimmune in Q3 2013 and held it in 7 quarters.
J. Goldman & Co's Altimmune position peaked at $714K in Q3 2022.
128 funds tracked by Wall St. Rank held Altimmune as of Q4 2022.

Based on J. Goldman & Co's 13F filing for Q4 2022, filed 14 Feb 2023.